Publication | Closed Access

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

Hematological MalignancyLymphoid NeoplasiaGhsg Hd13OncologyEarly-stage Favourable HodgkinClinical TrialsPharmacotherapyNon-inferiority TrialAdult T-cell Leukemia-lymphomaMedicineRadiation OncologyCancer ResearchHealth Sciences